Tags

Type your tag names separated by a space and hit enter

Protease Inhibitor Use in COVID-19.
SN Compr Clin Med. 2020 Aug 14 [Online ahead of print]SC

Abstract

The outbreak of a large plaque, novel coronavirus pneumonia (NCP), which also named Coronavirus Disease 2019 (COVID-19) by the WHO, has detrimentally affected the livelihood and health of people in China. During the spread of COVID-19, colleagues who have been working at the frontline have had to face many new challenges in the treatment and prevention of NCP. Therefore, we have provided suggestions for the diagnosis, treatment, and prevention of the novel coronavirus pneumonia in the current epidemic situation based on the latest reports and the experience of doctors treating COVID-19 in our hospital. We recommend lopinavir/ritonavir as the effective drugs for antiviral treatment according to our experience in administering lopinavir/ritonavir to COVID-19 patients and the successful cases of these drugs in treating MERS and SARS, but need more clinical data to prove their efficacy in treating COVID-19.

Authors+Show Affiliations

Clinical Medical Research Center, The Second Clinical Medical College of Jinan University (Shenzhen People's Hospital), 1017 North Road, Dongmen, Shenzhen, 518020 Guangdong People's Republic of China.Department of Nephrology, National Clinical Research Center for Infectious Diseases, The Second Affiliated Hospital of Southern University of Science and Technology (Shenzhen Third People's Hospital), Shenzhen, 518114 Guangdong People's Republic of China.Clinical Medical Research Center, The Second Clinical Medical College of Jinan University (Shenzhen People's Hospital), 1017 North Road, Dongmen, Shenzhen, 518020 Guangdong People's Republic of China.Clinical Medical Research Center, The Second Clinical Medical College of Jinan University (Shenzhen People's Hospital), 1017 North Road, Dongmen, Shenzhen, 518020 Guangdong People's Republic of China.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

32838187

Citation

Song, Yueqi, et al. "Protease Inhibitor Use in COVID-19." SN Comprehensive Clinical Medicine, 2020, pp. 1-8.
Song Y, Peng W, Tang D, et al. Protease Inhibitor Use in COVID-19. SN Compr Clin Med. 2020.
Song, Y., Peng, W., Tang, D., & Dai, Y. (2020). Protease Inhibitor Use in COVID-19. SN Comprehensive Clinical Medicine, 1-8. https://doi.org/10.1007/s42399-020-00448-0
Song Y, et al. Protease Inhibitor Use in COVID-19. SN Compr Clin Med. 2020 Aug 14;1-8. PubMed PMID: 32838187.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Protease Inhibitor Use in COVID-19. AU - Song,Yueqi, AU - Peng,Wujian, AU - Tang,Donge, AU - Dai,Yong, Y1 - 2020/08/14/ PY - 2020/08/06/accepted PY - 2020/8/25/entrez PY - 2020/8/25/pubmed PY - 2020/8/25/medline KW - Diagnosis KW - Lopinavir/ritonavir KW - Novel coronavirus pneumonia KW - Treatment SP - 1 EP - 8 JF - SN comprehensive clinical medicine JO - SN Compr Clin Med N2 - The outbreak of a large plaque, novel coronavirus pneumonia (NCP), which also named Coronavirus Disease 2019 (COVID-19) by the WHO, has detrimentally affected the livelihood and health of people in China. During the spread of COVID-19, colleagues who have been working at the frontline have had to face many new challenges in the treatment and prevention of NCP. Therefore, we have provided suggestions for the diagnosis, treatment, and prevention of the novel coronavirus pneumonia in the current epidemic situation based on the latest reports and the experience of doctors treating COVID-19 in our hospital. We recommend lopinavir/ritonavir as the effective drugs for antiviral treatment according to our experience in administering lopinavir/ritonavir to COVID-19 patients and the successful cases of these drugs in treating MERS and SARS, but need more clinical data to prove their efficacy in treating COVID-19. SN - 2523-8973 UR - https://www.unboundmedicine.com/medline/citation/32838187/Protease_Inhibitor_Use_in_COVID_19_ L2 - https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/32838187/ DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.